Contact l Sitemap

home industries issues reasearch weblog press

Home  » Industries » Pharmaceuticals

CorpWatch Exclusives

Gilead Sciences Under Investigation for Over-Charging for Hepatitis C Pill
by Pratap ChatterjeeCorpWatch Blog
July 21st, 2014
Gilead Sciences of San Francisco is under investigation by the U.S. Senate Finance Committee for charging $84,000 for a 12 week course of a new drug to treat hepatitis C. Gilead sells the exact same course for $900 in poor countries like Egypt and India.

Big Pharma Abandons New Tuberculosis Drug Research
by Fatima HansiaCorpWatch Blog
April 1st, 2014
Three major pharmaceutical companies - AstraZeneca, Johnson & Johnson and Pfizer - have recently delayed or canceled clinical trials for testing tuberculosis (TB) drugs in India and South Africa. Activists say this is symbolic of a trend by Big Pharma to abandon research into diseases that affect poor people.

Bayer CEO Says Drugs Developed For “Western Patients Who Can Afford It”
by Pratap ChatterjeeCorpWatch Blog
February 3rd, 2014
Bayer, the German pharmaceutical giant, is in hot water after CEO Marijn Dekkers told a Financial Times conference that the company designed medicines “for western patients who can afford it” not for the “Indian market.” The company has been critical of the Indian governments efforts to make cheap generic drugs available locally.

Bumper Year for Corporate Donations Reveals Profit Motives
by Rick CohenCorpWatch Blog
September 10th, 2013
U.S. corporations gave away $18.15 billion in charitable donations in 2012 – a combination of cash, grants, and in-kind goods - up 12.2 percent in nominal terms over the previous year. A closer look reveals profit motives, notably for pharmaceutical companies and retail chain Wal-Mart.

GlaxoSmithKline Alleged to Pay Bribes in China
by Pratap ChatterjeeCorpWatch Blog
July 15th, 2013
GlaxoSmithKline (GSK) has been accused of bribing doctors in China in order to boost sales. Chinese government officials say they have uncovered evidence of a bribery scheme involving 700 travel agencies who were used to funnel as much as three billion yuan ($480 million) in payments.

Myriad Loses Patent to Breast Cancer Genetic Test
by Richard SmallteacherCorpWatch Blog
June 13th, 2013
Myriad Genetics has lost its right to be the exclusive U.S. commercial provider of genetic screening tests for breast cancer or ovarian cancer. The American Civil Liberties Union (ACLU), which sued the company, claimed that the patent would limit scientific research as well as health care options for women.

Ranbaxy Pays $500 Million Fine for Selling Bad Batches of Generic Medicines
by Pratap ChatterjeeCorpWatch Blog
May 14th, 2013
Ranbaxy, a subsidiary of Japanese pharmaceutical company Daiichi Sankyo, has paid a $500 million fine and pled guilty to selling adulterated drugs manufactured in India. The settlement comes 16 months after the company signed an agreement with U.S. authorities to change its ways.

Medical Trial Data Activists Score Win Over Glaxo
by Pratap ChatterjeeCorpWatch Blog
February 7th, 2013
All data on completed medical experiments are to be made available to the general public by GlaxoSmithKline, the biggest UK pharmaceutical company. The announcement is a major win for the AllTrials campaign mounted by healthcare activists as well as researchers that has gathered widespread support.

Grey Market Drugs: Profiting from Poorly Managed U.S. Health Care
by Terry J. AllenSpecial to CorpWatch
January 22nd, 2012
Scalpers are doing a booming business in key medical drugs by taking advantage of U.S. patients and hospitals when they are desperate for supplies from the poorly regulated $46 billion global contract-manufacturing industry.

Doctoring the Evidence: GlaxoSmithKline Pushes Depression Drug
by Shelley JofreSpecial to Corp Watch
July 30th, 2007
GlaxoSmithKline provides research funding to doctors who write favorable opinions of depression drugs for children, despite evidence from clinical trials that the medication can cause anger and even suicide.

Merck's Murky Dealings: HPV Vaccine Lobby Backfires
by Terry J. AllenSpecial to CorpWatch
March 7th, 2007
Merck's lobbying campaign for mandatory vaccination of school girls provided funding for a prominent women's non-profit. The ensuing uproar has created a backlash against the pharmaceutical giant.

University, Inc.
by Jennifer BordenSpecial to CorpWatch
April 11th, 2005
From research patents to high-stakes partnerships, Jennifer Washburn spent years researching the links between industry and the American University. In this exclusive interview with CorpWatch's Jennifer Borden, Washburn talks about what she found, why it matters and what you can do about it.

Exporting Cures, Importing Misery
by By Stan CoxAlterNet
January 19th, 2005
The Kazipally industrial area – once good farm country – now accounts for more than one-third of India's pharmaceutical industry, meaning skyrocketing rates of cancer, heart disease and birth defects for its residents.

Biotechnology's Third Generation
by Carmelo Ruiz-MarreroSpecial to CorpWatch
April 5th, 2002
From golden rice to anti-viral tomatoes, is the biotech industry's third generation good medicine or good marketing? And, activists ask, what are the environmental consequences?

War Profiteering: Bayer, Anthrax and International Trade
by Kavaljit SinghAsia-Europe Dialogue Project
November 5th, 2001
US officials have refused to bust Bayer's monopoly on anthrax drugs, even though generic drugs would save $millions. Bayer's patent was protected under the WTO. Now those rights are challenged.

Silence = Death: AIDS, Africa and Pharmaceuticals
by Stephen LewisToronto Globe and Mail
January 26th, 2001
While 25 million Africans are living with AIDS, Northern pharmaceutical companies and governments are turning their back on the greatest tragedy of our time according to former deputy head of UNICEF.